Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Capitol Capsule: Stage Set For More Federal Circuit Biosimilars Interpretive Dancing

This article was originally published in Scrip

Executive Summary

With an appeal filed last week by Apotex Inc. in a lawsuit brought against it by Amgen Inc. it looks like the US Court of Appeals for the Federal Circuit will have another chance to do some more interpretive dancing of the 2010 law that gave the FDA the authority to approve biosimilars – the Biologics Price Competition and Innovation Act (BPCIA).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC063962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel